Intrathecal Stem Cell Administration

Lumbar puncture is a well-established medical procedure performed routinely in pediatric medicine. When carried out by experienced physicians, it carries a low risk of complications. Every child undergoes a thorough medical evaluation before being considered a suitable candidate.

The procedure is performed under appropriate sedation or anesthesia for pediatric patients to ensure comfort. Post-procedure, some children may experience a mild headache that typically resolves within 24–48 hours with rest and hydration.

Intrathecal administration delivers cells directly into the cerebrospinal fluid, providing more direct exposure to the central nervous system. It is considered when the clinical goals emphasize CNS-related targets such as neuroinflammation, neural signaling, or developmental concerns where systemic IV delivery alone may be less direct.

Candidacy depends on the child's neurological history, imaging when relevant, coagulation status, current medications, seizure history, and overall medical eligibility. Not every child is a suitable candidate, and a clinical review is mandatory before this route is recommended.

The child is positioned and given appropriate pediatric sedation. Using sterile technique, a thin spinal needle is introduced into the lumbar subarachnoid space, a small volume of CSF is sampled if needed, and the prepared cell product is slowly infused. The child is then monitored in a recovery area.

The intrathecal procedure itself is typically completed within 20–30 minutes. Including sedation preparation and post-procedure monitoring, families should plan for a half-day clinical visit on the day of administration.

Children are typically advised to lie flat and rest for several hours after the procedure, with gentle activity and good hydration over the following 24–48 hours. Strenuous activity is avoided briefly. Detailed aftercare instructions are provided in writing before discharge.

Yes. Many personalized protocols combine intrathecal administration for CNS-focused exposure with IV infusions for systemic immunomodulation, and sometimes intranasal exosomes for direct neural signaling. Combinations are always decided as part of the individualized treatment plan.

Cells are processed in GMP-aligned facilities and prepared in a sterile, preservative-free vehicle suitable for intrathecal use. Each batch is verified for sterility, endotoxin, viability, and identity before being released for clinical administration.

Published clinical data on intrathecal MSC administration generally describe a favorable short-term safety profile when performed under appropriate medical oversight. Long-term data continues to be collected as a part of ongoing research. Honest discussion of what is and is not known is part of every consultation.

No. Intrathecal MSC therapy for autism is not approved as a standard treatment by agencies such as the FDA or EMA. It is offered as an investigational regenerative medicine option within a regulated Turkish medical framework, and outcomes are never guaranteed.

Most personalized plans involve a small number of intrathecal sessions over a structured treatment course, rather than repeated frequent procedures. The specific number is decided based on clinical reasoning and the child's response, not on a fixed package.